Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)
China · Delayed Price · Currency is CNY 24.20
-0.54 (-2.18%)
At close: May 12, 2026
SHA:688739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,305 | 1,390 | 1,676 | 1,750 | 1,815 | 2,088 | |
Revenue Growth (YoY) | -21.84% | -17.06% | -4.22% | -3.58% | -13.08% | 4.63% |
Cost of Revenue | 390.29 | 405.79 | 319.24 | 342.56 | 243.28 | 220.37 |
Gross Profit | 914.95 | 984.5 | 1,357 | 1,408 | 1,572 | 1,868 |
Selling, General & Admin | 611.91 | 610.49 | 659.02 | 648.29 | 588.41 | 603.58 |
Research & Development | 293.29 | 292.93 | 281.94 | 219.96 | 210.89 | 236.82 |
Other Operating Expenses | 17.85 | 15.28 | 22.57 | 21.86 | 22.1 | 20.82 |
Operating Expenses | 930.57 | 927.14 | 972.19 | 902.89 | 836.49 | 877.65 |
Operating Income | -15.62 | 57.36 | 384.8 | 504.66 | 735.23 | 990.02 |
Interest Expense | -1.37 | -1.43 | -1.58 | -1.42 | -1.32 | -1.54 |
Interest & Investment Income | 50.09 | 53.11 | 70.5 | 96.81 | 128.3 | 45.81 |
Currency Exchange Gain (Loss) | 0.42 | 0.42 | 0.84 | 2.47 | 2.5 | -0.48 |
Other Non Operating Income (Expenses) | -3.7 | -2.06 | -0.28 | -0.82 | -0.47 | -0.42 |
EBT Excluding Unusual Items | 29.82 | 107.41 | 454.28 | 601.71 | 864.25 | 1,033 |
Gain (Loss) on Sale of Investments | 47.74 | 51.43 | -75.57 | -45.29 | -43.63 | -25.53 |
Gain (Loss) on Sale of Assets | -0.51 | -0.51 | -1.72 | 1.61 | -0.79 | -0.69 |
Asset Writedown | 2.35 | - | - | - | - | - |
Other Unusual Items | 11.28 | 11.28 | 26.03 | 18.36 | 18.25 | 23.81 |
Pretax Income | 90.68 | 169.6 | 403.02 | 576.38 | 838.07 | 1,031 |
Income Tax Expense | 33.02 | 37.81 | 60.2 | 110.46 | 124.05 | 138.49 |
Net Income | 57.66 | 131.79 | 342.82 | 465.92 | 714.02 | 892.49 |
Net Income to Common | 57.66 | 131.79 | 342.82 | 465.92 | 714.02 | 892.49 |
Net Income Growth | -82.71% | -61.56% | -26.42% | -34.75% | -20.00% | -2.80% |
Shares Outstanding (Basic) | 404 | 412 | 413 | 416 | 418 | 381 |
Shares Outstanding (Diluted) | 404 | 412 | 413 | 416 | 418 | 381 |
Shares Change (YoY) | -2.49% | -0.29% | -0.71% | -0.37% | 9.48% | 1.77% |
EPS (Basic) | 0.14 | 0.32 | 0.83 | 1.12 | 1.71 | 2.34 |
EPS (Diluted) | 0.14 | 0.32 | 0.83 | 1.12 | 1.71 | 2.34 |
EPS Growth | -82.27% | -61.45% | -25.89% | -34.50% | -26.92% | -4.49% |
Free Cash Flow | 42.45 | 32.78 | 138.48 | 125.02 | 34.89 | -1.97 |
Free Cash Flow Per Share | 0.10 | 0.08 | 0.34 | 0.30 | 0.08 | -0.01 |
Dividend Per Share | 0.100 | 0.100 | 0.800 | 0.800 | 1.000 | 1.000 |
Dividend Growth | -87.50% | -87.50% | - | -20.00% | - | - |
Gross Margin | 70.10% | 70.81% | 80.95% | 80.43% | 86.60% | 89.45% |
Operating Margin | -1.20% | 4.13% | 22.96% | 28.84% | 40.51% | 47.41% |
Profit Margin | 4.42% | 9.48% | 20.45% | 26.62% | 39.34% | 42.74% |
Free Cash Flow Margin | 3.25% | 2.36% | 8.26% | 7.14% | 1.92% | -0.09% |
EBITDA | 155.13 | 227.46 | 552.31 | 624.89 | 851.42 | 1,101 |
EBITDA Margin | 11.88% | 16.36% | 32.95% | 35.71% | 46.91% | 52.73% |
D&A For EBITDA | 170.75 | 170.1 | 167.51 | 120.24 | 116.19 | 111.07 |
EBIT | -15.62 | 57.36 | 384.8 | 504.66 | 735.23 | 990.02 |
EBIT Margin | -1.20% | 4.13% | 22.96% | 28.84% | 40.51% | 47.41% |
Effective Tax Rate | 36.41% | 22.30% | 14.94% | 19.16% | 14.80% | 13.43% |
Revenue as Reported | 1,305 | 1,390 | 1,676 | 1,750 | 1,815 | 2,088 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.